Scimera BioScience launches probiotic to replace 'good bacteria' in the gut

MIAMI — Scimera BioScience on Thursday announced the launch of a novel probiotic formulation, Asprega ProPac, to address the gastrointestinal side effects of antibiotic therapy including antibiotic-associated diarrhea. Unique to ProPac, Scimera packages its probiotic in a convenient 10-day course.

According to the company, as many as 30% of patients on an antibiotic regimen have gastrointestinal distress or ADD. ProPac, with a complex blend of 11 probiotic strains and saccharomyces boulardii yeast, addresses the "good bacteria" sometimes disturbed during antibiotic therapy.

"We have seen plenty of evidence over the past half-dozen years that probiotics can prevent antibiotic-associated diarrhea for about 50% to 60% of patients who suffer from symptoms," stated Frederick Chaleff, president and CEO of Scimera BioScience. "Now, we can offer patients an affordable option to address the side effects from taking their antibiotics."

Like this story? Find us on Facebook for more insight, analysis and the latest in drug store news. Join the conversation.